DIAGNOS Announces Private Placement
September 13 2019 - 11:00AM
DIAGNOS Inc. (“DIAGNOS”, the “Corporation” or the “Issuer”) (TSX
Venture: ADK) (OTCQB: DGNOF), a leader in early detection of
critical health issues through the use of Artificial Intelligence
(AI), announces a private placement (“Private placement”) of up to
2,500,000 units (each a “Unit”) issued at $0.20 per Unit, for gross
proceeds of up to $500,000. Each Unit consists of;
- one common share (“Share”), and
- one stock warrant (“Warrant”) entitling the holder to purchase
one Share per Warrant at a price of $0.25 per Share, for a period
of 18 months from the issue date.
The proceeds will mainly be used to fund sales
and marketing as well as administrative expenses.
Shares issued as part of the Private placement
as well as the underlying Shares to be issued upon exercise of the
Warrants are subject to a statutory four-month hold period from the
issue date.
The Private placement is subject to receipt of
all required approvals, including the approval of the TSX Venture
Exchange, as well as the execution of formal documentation.
All monies quoted in this press release shall be
stated and paid in lawful money of Canada.
About DIAGNOSDIAGNOS is a publicly-traded
Canadian corporation with a mission of early detection of critical
health issues through the use of its Artificial Intelligence (“AI”)
tool CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time and has been cleared for
commercialization by several regulatory authorities such as Health
Canada, the U.S. Food and Drug Administration and the European
Union.
Additional information is available at
www.diagnos.com and www.sedar.com. For further information, please
contact:
Mr. André Larente, President |
DIAGNOS Inc. |
Tel: 450-678-8882 ext. 224 |
alarente@diagnos.ca |
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publically update or revise any forward-looking information,
whether as a result of new information, future events or otherwise.
The forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Diagnos (TSXV:ADK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Apr 2023 to Apr 2024